NASDAQ · INBX
Healthcare · Biotechnology
$112.86
Down-$1.44 (-1.28%)
Updated Sep 11, 2026, 12:05 AM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
INBX closed at $112.86 after 19 trading sessions, up 16.34% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $117.38 | $128.54 | $112.03 | $112.86 | 677.83K |
| Sep 8, 2026 | $117.22 | $120.1825 | $94.0001 | $114.34 | 1.68M |
| Sep 4, 2026 | $121.04 | $124.19 | $120.48 | $121.17 | 196.51K |
| Sep 3, 2026 | $125.20 | $126.00 | $120.17 | $122.26 | 151.71K |
| Sep 2, 2026 | $125.61 | $127.7525 | $121.25 | $124.97 | 189.89K |
| Sep 1, 2026 | $124.98 | $129.88 | $120.62 | $124.66 | 275.91K |
| Aug 31, 2026 | $123.39 | $128.87 | $121.59 | $126.70 | 388.98K |
| Aug 28, 2026 | $123.80 | $126.04 | $119.38 | $123.41 | 241.48K |
| Aug 27, 2026 | $124.27 | $127.34 | $122.355 | $123.93 | 310.88K |
| Aug 26, 2026 | $123.00 | $131.01 | $119.435 | $125.34 | 302.86K |
| Aug 25, 2026 | $105.50 | $126.50 | $104.71 | $122.72 | 510.62K |
| Aug 24, 2026 | $105.00 | $105.14 | $94.20 | $104.94 | 373.62K |
| Aug 21, 2026 | $100.76 | $105.65 | $99.05 | $103.63 | 220.74K |
| Aug 20, 2026 | $98.65 | $102.4999 | $96.565 | $99.15 | 351.49K |
| Aug 19, 2026 | $96.01 | $102.25 | $95.27 | $101.48 | 310.66K |
| Aug 18, 2026 | $89.83 | $94.89 | $89.00 | $94.62 | 311.23K |
| Aug 17, 2026 | $87.06 | $92.99 | $85.06 | $92.01 | 231.74K |
| Aug 14, 2026 | $91.80 | $96.06 | $87.01 | $88.37 | 268.29K |
| Aug 13, 2026 | $99.95 | $101.00 | $94.32 | $97.01 | 251.2K |
The latest Smart Investors Daily articles mentioning INBX.
INBX research
Company profile and research snapshot.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 8, 2026 | Stifel | Buy | — |
| Aug 22, 2025 | JMP Securities | Market Perform | — |
| May 15, 2025 | JMP Securities | Market Perform | — |
| Mar 18, 2025 | Citizens Capital Markets | Market Perform | — |
No generated briefing is available yet.
Yahoo · Sep 8, 2026
Inhibrx Biosciences (NASDAQ:INBX) shares gained 6% on Tuesday after the biotechnology company reported encouraging Phase 2 results for INBRX-106 in combination with pembrolizumab in patients with head and neck cancer. Data from the HexAgon study showed a confirmed objective response rate of 48.
Yahoo · Sep 8, 2026
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the primary endpoint results from the randomized and controlled Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control
Yahoo · Sep 4, 2026
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced that it will host a live webcast presentation on Tuesday, September 8, 2026 at 5:00 a.m. Pacific Time, to provide primary endpoint results from the randomized and controlled Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 a
Benzinga · Sep 4, 2026
– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT –SAN DIEGO, Sept. 4, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INBX.
